SNTA Synta Pharmaceuticals Corp. featured news, full reports, and detailed charts
Synta Pharmaceuticals Corp. (SNTA) Wrap Up:
We are a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to extend and enhance the lives of patients with severe medical conditions, including cancer and chronic inflammatory diseases. We have a unique chemical compound library, an integrated discovery engine, and a diverse pipeline of clinical- and preclinical-stage drug candidates with distinct mechanisms of action and novel chemical structures. We have three drug candidates in clinical trials, one drug candidate in preclinical studies, and one program undergoing lead optimization. We discovered and developed each of our drug candidates internally using our compound library and discovery capabilities. At present, other than our lead drug candidate, elesclomol, we retain all rights to each of our drug candidates and programs, across all geographic markets and therapeutic indications. ... More..."http://secfilings.nasdaq.com/edgar_conv_html%2f2008%2f03%2f20%2f0001047469-08-003112.html#FIS_BUSINESS"Synta Pharmaceuticals Corp. (SNTA:NASDAQ)
Snapshot of Synta Pharmaceuticals Corp. (SNTA)
|
OPEN
$3.81
|
PREVIOUS CLOSE
$3.82
|
|
|
DAY HIGH
$3.85
|
DAY LOW
$3.75
|
|
|
52 WEEK HIGH
02/2/09 - $9.55
|
52 WEEK LOW
03/2/09 - $1.20
|
|
|
MARKET CAP
129.8M
|
AVERAGE VOLUME 3 mo
112.4K
|
|
|
DILUTED EPS TTM
$1.77
|
SHARES OUTSTANDING
34.0M
|
|
|
SNTA Does Not Pay Dividends
|
P/E TTM
2.2x
|
|
| K = Thousands M = Millions B = Billions | ||
SNTA Top Compensated Officers
Executives, Board Directors
Key developments for Synta Pharmaceuticals Corp. (SNTA)
Synta Pharmaceuticals Corp. reported unaudited consolidated earnings results for the third quarter and nine months ended September 30, 2009. For the quarter, the company reported income from operations of $118,172,000, net income of $118,119,000 or $3.48 diluted per share on total collaboration revenues of $130,405,000 against loss from operations of $26,451,000, net loss of $26,321,000 or $0.78 diluted loss per share on total collaboration revenues of $1,272,000 for the same period a year ago. For the nine months, the company reported income from operations of $86,284,000, net income of $86,125,000 or $2.53 diluted per share on total collaboration revenues of $139,565,000 against loss from operations of $67,843,000, net loss of $66,665,000 or $1.98 diluted loss per share on total collaboration revenues of $1,979,000 for the same period a year ago.
Synta Pharmaceuticals Corp. expected to Report Fiscal Year 2009 Results on March 22, 2010. This event was calculated by Capital IQ (Created on November 4, 2009).
On October 21, 2009, Synta Pharmaceuticals Corp. announced that James G. Barsoum, Ph.D., Senior Vice President, Research informed the company of his intention to resign. The effective date of Dr. Barsoum’s resignation will be October 30, 2009.
SNTA Competitors
| Company | Last | Change |
| Affymax Inc | $20.07 USD | +0.41 |
| Cytokinetics Incorporated | $3.40 USD | -0.05 |
| Idera Pharmaceuticals Inc | $4.83 USD | +0.14 |
| Infinity Pharmaceuticals Inc | $5.95 USD | -0.30 |
| MAP Pharmaceuticals Inc | $8.75 USD | +0.23 |
| Market data is delayed at least 20 minutes. | ||
Industry Analysis
| Valuation | SNTA | Industry Range |
| Price/Earnings | 2.2x |
|
| Price/Sales | 0.9x |
|
| Price/Book | 4.2x |
|
| Price/Cash Flow | 2.2x |
|
| TEV/Sales | 0.5x |
|
|
SNTA |
||
SNTA transactions
| Type Date |
Target | |
| No transactions in the last 6 months. | ||